Tibulizumab

Phase 2Monoclonal antibody

ZZura Bio Inc

Tibulizumab is one of 8 biologic programs targeting Systemic Sclerosis (SSc). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Sclerosis (ssc)Active, not recruiting

Hidradenitis Suppurativa (HS)Active, not recruiting

Systemic Sclerosis (ssc)Phase 2

Active, not recruiting

Hidradenitis Suppurativa (HS)Phase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Hidradenitis Suppurativa (HS)

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Approved

1 2

Povorcitinib

Incyte

Phase 3

3 3

Bimzelx

UCB

Phase 2

1 4

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 5

Tibulizumab

ZZura Bio Inc

Phase 2

1 6

Soquelitinib

CCorvus Pharmaceuticals, Inc.

Phase 1

1 7

NAV-240

NNavigator Medicines, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Hidradenitis Suppurativa (HS)

NCT06993610

Q1 2028

Phase 2Active, not recruiting

Systemic Sclerosis (ssc)

NCT06843239

Clinical

Trials by Indication[1]

Primary Sjogren's Syndrome1 trial

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

Withdrawn·MMatthew C. Baker·Phase 2/3·NCT04563195

Systemic Sclerosis (SSc)1 trial

A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis

Active, not recruiting·ZZura Bio Inc·Phase 2·NCT06843239·80 enrolled

Hidradenitis Suppurativa (HS)1 trial

A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa

Active, not recruiting·ZZura Bio Inc·Phase 2·NCT06993610·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tibulizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tibulizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tibulizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zura Bio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: ZZura Bio Inc

Tibulizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Trials by Indication[1]

Primary Sjogren's Syndrome1 trial

Systemic Sclerosis (SSc)1 trial

Hidradenitis Suppurativa (HS)1 trial

References

Drug Info

Quick Facts

Related News